RegeneRx Biopharmaceuticals, Inc. Logo

RegeneRx Biopharmaceuticals, Inc.

RGRX

(1.8)
Stock Price

0,07 USD

0% ROA

0% ROE

0x PER

Market Cap.

2.096,00 USD

0% DER

0% Yield

0% NPM

RegeneRx Biopharmaceuticals, Inc. Stock Analysis

RegeneRx Biopharmaceuticals, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

RegeneRx Biopharmaceuticals, Inc. Fundamental Stock Analysis
# Analysis Rating
1 ROE

The stock's ROE exceeds expectations (56.07%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

2 PBV

The stock's low PBV ratio (-0.37x) suggests it's undervalued, making it an attractive opportunity for investors.

3 DER

The stock has a low debt to equity ratio (-40%), which means it has a small amount of debt compared to the ownership it holds

4 Graham Number

Based on the Graham number, this company's stock price appears to be lower than its intrinsic value, signaling a potentially favorable investment choice.

5 ROA

The stock's ROA (-989.81%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

7 Net Profit Growth

This company's net profit has remained stagnant over the past five years, indicating a lack of growth and making it a less favorable investment option.

8 Assets Growth

Company has experienced no growth in revenue over the past three years, suggesting limited profitability and making it a less desirable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

No dividends from the company in the past three years raises doubts about its profitability for shareholders.

11 Buffet Intrinsic Value

Based on Warren Buffett's formula, the company's stock seems overpriced (0), indicating a potential drawback for investors as its market price exceeds its estimated intrinsic value.

RegeneRx Biopharmaceuticals, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

RegeneRx Biopharmaceuticals, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

RegeneRx Biopharmaceuticals, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

RegeneRx Biopharmaceuticals, Inc. Revenue
Year Revenue Growth
1995 105.591
1996 542.243 80.53%
1997 215.034 -152.17%
1998 3.265 -6486.03%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 272.491 100%
2007 240.324 -13.38%
2008 168.412 -42.7%
2009 0 0%
2010 849.539 100%
2011 1.511.572 43.8%
2012 1.342.844 -12.56%
2013 29.484 -4454.48%
2014 0 0%
2015 60.612 100%
2016 93.308 35.04%
2017 56.652 -64.7%
2018 69.667 18.68%
2019 76.762 9.24%
2020 76.761 -0%
2021 76.761 0%
2022 76.761 0%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

RegeneRx Biopharmaceuticals, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
1995 2.751.744
1996 1.052.352 -161.49%
1997 85.695 -1128.02%
1998 41.339 -107.3%
1999 1.276 -3139.73%
2000 64.795 98.03%
2001 139.115 53.42%
2002 885.631 84.29%
2003 775.752 -14.16%
2004 2.184.314 64.49%
2005 4.028.857 45.78%
2006 6.396.524 37.01%
2007 8.887.255 28.03%
2008 7.109.808 -25%
2009 3.724.514 -90.89%
2010 2.707.909 -37.54%
2011 5.067.085 46.56%
2012 1.161.967 -336.08%
2013 188.643 -515.96%
2014 367.275 48.64%
2015 203.185 -80.76%
2016 237.344 14.39%
2017 143.911 -64.92%
2018 81.043 -77.57%
2019 65.107 -24.48%
2020 4.921 -1223.04%
2021 6.638 25.87%
2022 0 0%
2023 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

RegeneRx Biopharmaceuticals, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 1.158.450 100%
2005 1.640.670 29.39%
2006 2.665.652 38.45%
2007 3.197.685 16.64%
2008 3.845.346 16.84%
2009 2.781.790 -38.23%
2010 3.173.729 12.35%
2011 2.456.028 -29.22%
2012 1.022.207 -140.27%
2013 755.092 -35.38%
2014 1.188.211 36.45%
2015 1.566.962 24.17%
2016 1.529.983 -2.42%
2017 1.357.371 -12.72%
2018 1.311.993 -3.46%
2019 1.273.536 -3.02%
2020 1.366.383 6.8%
2021 1.398.634 2.31%
2022 1.478.752 5.42%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

RegeneRx Biopharmaceuticals, Inc. EBITDA
Year EBITDA Growth
1995 -4.549.656
1996 -1.376.204 -230.59%
1997 -650.848 -111.45%
1998 -2.291.797 71.6%
1999 291.298 886.75%
2000 -1.167.087 124.96%
2001 -691.245 -68.84%
2002 -1.452.631 52.41%
2003 -1.620.396 10.35%
2004 -3.338.589 51.46%
2005 -5.653.901 40.95%
2006 -8.771.573 35.54%
2007 -11.823.419 25.81%
2008 -10.767.346 -9.81%
2009 -6.489.757 -65.91%
2010 -5.022.363 -29.22%
2011 -6.002.463 16.33%
2012 -833.730 -619.95%
2013 -909.236 8.3%
2014 -1.550.510 41.36%
2015 -1.706.031 9.12%
2016 -1.670.693 -2.12%
2017 -1.441.582 -15.89%
2018 -1.903.520 24.27%
2019 -1.249.419 -52.35%
2020 -1.290.737 3.2%
2021 -1.328.277 2.83%
2022 -1.401.808 5.25%
2023 0 0%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

RegeneRx Biopharmaceuticals, Inc. Gross Profit
Year Gross Profit Growth
1995 105.591
1996 542.243 80.53%
1997 215.034 -152.17%
1998 3.265 -6486.03%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 272.491 100%
2007 240.324 -13.38%
2008 168.412 -42.7%
2009 0 0%
2010 849.539 100%
2011 1.511.572 43.8%
2012 1.342.844 -12.56%
2013 29.295 -4483.87%
2014 -367 8082.29%
2015 60.408 100.61%
2016 93.070 35.09%
2017 53.604 -73.63%
2018 69.585 22.97%
2019 76.696 9.27%
2020 76.756 0.08%
2021 76.754 -0%
2022 76.761 0.01%
2023 0 0%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

RegeneRx Biopharmaceuticals, Inc. Net Profit
Year Net Profit Growth
1995 -4.092.197
1996 -1.636.027 -150.13%
1997 -795.430 -105.68%
1998 1.761.568 145.15%
1999 -711.232 347.68%
2000 1.041.432 168.29%
2001 -150.609 791.48%
2002 -1.404.547 89.28%
2003 -1.659.875 15.38%
2004 -3.326.399 50.1%
2005 -5.454.851 39.02%
2006 -8.266.981 34.02%
2007 -11.178.158 26.04%
2008 -10.636.965 -5.09%
2009 -6.493.860 -63.8%
2010 -5.023.912 -29.26%
2011 -6.007.052 16.37%
2012 -847.002 -609.21%
2013 -671.343 -26.17%
2014 -2.753.642 75.62%
2015 -5.270.483 47.75%
2016 229.125 2400.27%
2017 286.487 20.02%
2018 -1.993.553 114.37%
2019 -1.557.657 -27.98%
2020 -1.752.193 11.1%
2021 -1.922.399 8.85%
2022 -1.727.272 -11.3%
2023 0 0%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

RegeneRx Biopharmaceuticals, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 0 0%
2000 0 0%
2001 0 0%
2002 0 0%
2003 0 0%
2004 0 0%
2005 0 0%
2006 0 0%
2007 0 0%
2008 0 0%
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

RegeneRx Biopharmaceuticals, Inc. Free Cashflow
Year Free Cashflow Growth
1995 593.618
1996 -441.772 234.37%
1997 -492.356 10.27%
1998 -466.595 -5.52%
1999 -381.416 -22.33%
2000 -576.091 33.79%
2001 -476.814 -20.82%
2002 -1.291.337 63.08%
2003 -1.650.937 21.78%
2004 -2.952.592 44.09%
2005 -4.830.644 38.88%
2006 -7.237.334 33.25%
2007 -8.820.001 17.94%
2008 -10.570.406 16.56%
2009 -6.151.665 -71.83%
2010 -5.023.040 -22.47%
2011 -5.421.076 7.34%
2012 -274.187 -1877.15%
2013 -781.599 64.92%
2014 -1.717.263 54.49%
2015 -526.416 -226.22%
2016 -1.068.132 50.72%
2017 -663.085 -61.09%
2018 -888.294 25.35%
2019 -1.137.970 21.94%
2020 -1.006.929 -13.01%
2021 -990.296 -1.68%
2022 -940.718 -5.27%
2023 0 0%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

RegeneRx Biopharmaceuticals, Inc. Operating Cashflow
Year Operating Cashflow Growth
1995 593.618
1996 -441.772 234.37%
1997 -492.356 10.27%
1998 -466.595 -5.52%
1999 -379.222 -23.04%
2000 -576.091 34.17%
2001 -475.008 -21.28%
2002 -1.287.129 63.1%
2003 -1.649.083 21.95%
2004 -2.950.994 44.12%
2005 -4.459.404 33.83%
2006 -7.220.058 38.24%
2007 -8.807.767 18.03%
2008 -10.570.406 16.68%
2009 -6.151.665 -71.83%
2010 -4.996.856 -23.11%
2011 -5.419.992 7.81%
2012 -274.187 -1876.75%
2013 -781.599 64.92%
2014 -1.703.943 54.13%
2015 -525.340 -224.35%
2016 -1.068.132 50.82%
2017 -663.085 -61.09%
2018 -888.294 25.35%
2019 -1.137.970 21.94%
2020 -1.006.929 -13.01%
2021 -990.296 -1.68%
2022 -940.718 -5.27%
2023 0 0%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

RegeneRx Biopharmaceuticals, Inc. Capital Expenditure
Year Capital Expenditure Growth
1995 0
1996 0 0%
1997 0 0%
1998 0 0%
1999 2.194 100%
2000 0 0%
2001 1.806 100%
2002 4.208 57.08%
2003 1.854 -126.97%
2004 1.598 -16.02%
2005 371.240 99.57%
2006 17.276 -2048.88%
2007 12.234 -41.21%
2008 0 0%
2009 0 0%
2010 26.184 100%
2011 1.084 -2315.5%
2012 0 0%
2013 0 0%
2014 13.320 100%
2015 1.076 -1137.92%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

RegeneRx Biopharmaceuticals, Inc. Equity
Year Equity Growth
1995 -37.204
1996 -1.638.231 97.73%
1997 -2.078.661 21.19%
1998 -1.279.916 -62.41%
1999 -394.999 -224.03%
2000 254.196 255.39%
2001 19.998 -1171.11%
2002 309.787 93.54%
2003 916.770 66.21%
2004 2.708.579 66.15%
2005 7.010.507 61.36%
2006 16.252.335 56.86%
2007 6.152.724 -164.15%
2008 4.596.664 -33.85%
2009 3.703.350 -24.12%
2010 3.611.417 -2.55%
2011 -427.065 945.64%
2012 -1.023.289 58.27%
2013 -1.621.409 36.89%
2014 -1.711.619 5.27%
2015 -6.742.396 74.61%
2016 -6.066.558 -11.14%
2017 -4.116.292 -47.38%
2018 -2.212.053 -86.08%
2019 -2.340.108 5.47%
2020 -2.823.944 17.13%
2021 -2.229.879 -26.64%
2022 -3.445.471 35.28%
2023 0 0%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

RegeneRx Biopharmaceuticals, Inc. Assets
Year Assets Growth
1995 1.197.447
1996 313.268 -282.24%
1997 71.858 -335.95%
1998 449.767 84.02%
1999 932.363 51.76%
2000 499.657 -86.6%
2001 124.050 -302.79%
2002 546.933 77.32%
2003 1.109.818 50.72%
2004 3.288.501 66.25%
2005 7.724.634 57.43%
2006 17.501.625 55.86%
2007 8.621.793 -102.99%
2008 5.922.576 -45.58%
2009 4.583.754 -29.21%
2010 4.228.056 -8.41%
2011 383.594 -1002.22%
2012 356.621 -7.56%
2013 42.730 -734.59%
2014 949.191 95.5%
2015 358.223 -164.97%
2016 862.402 58.46%
2017 227.073 -279.79%
2018 281.040 19.2%
2019 711.760 60.51%
2020 551.788 -28.99%
2021 1.284.965 57.06%
2022 382.177 -236.22%
2023 0 0%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

RegeneRx Biopharmaceuticals, Inc. Liabilities
Year Liabilities Growth
1995 1.234.651
1996 1.951.499 36.73%
1997 2.150.519 9.25%
1998 1.729.683 -24.33%
1999 1.327.362 -30.31%
2000 245.461 -440.76%
2001 104.052 -135.9%
2002 237.146 56.12%
2003 193.048 -22.84%
2004 579.922 66.71%
2005 714.127 18.79%
2006 1.249.290 42.84%
2007 2.469.069 49.4%
2008 1.325.912 -86.22%
2009 880.404 -50.6%
2010 616.639 -42.77%
2011 810.659 23.93%
2012 1.379.910 41.25%
2013 1.664.139 17.08%
2014 2.660.810 37.46%
2015 7.100.619 62.53%
2016 6.928.960 -2.48%
2017 4.343.365 -59.53%
2018 2.493.093 -74.22%
2019 3.051.868 18.31%
2020 3.375.732 9.59%
2021 3.514.844 3.96%
2022 3.827.648 8.17%
2023 0 0%

RegeneRx Biopharmaceuticals, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0
Net Income per Share
0
Price to Earning Ratio
0x
Price To Sales Ratio
0x
POCF Ratio
0
PFCF Ratio
0
Price to Book Ratio
0
EV to Sales
0
EV Over EBITDA
0
EV to Operating CashFlow
0
EV to FreeCashFlow
0
Earnings Yield
0
FreeCashFlow Yield
0
Market Cap
0,00 Bil.
Enterprise Value
0,00 Bil.
Graham Number
0
Graham NetNet
0

Income Statement Metrics

Net Income per Share
0
Income Quality
0
ROE
0
Return On Assets
0
Return On Capital Employed
0
Net Income per EBT
0
EBT Per Ebit
0
Ebit per Revenue
0
Effective Tax Rate
0

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
0
Stock Based Compensation to Revenue
0
Gross Profit Margin
0
Operating Profit Margin
0
Pretax Profit Margin
0
Net Profit Margin
0

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
0
Free CashFlow per Share
0
Capex to Operating CashFlow
0
Capex to Revenue
0
Capex to Depreciation
0
Return on Invested Capital
0
Return on Tangible Assets
0
Days Sales Outstanding
0
Days Payables Outstanding
0
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,00
Book Value per Share
0,00
Tangible Book Value per Share
0
Shareholders Equity per Share
0
Interest Debt per Share
0
Debt to Equity
0
Debt to Assets
0
Net Debt to EBITDA
0
Current Ratio
0
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
0,00 Bil.
Invested Capital
0
Working Capital
0,00 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

RegeneRx Biopharmaceuticals, Inc. Dividends
Year Dividends Growth

RegeneRx Biopharmaceuticals, Inc. Profile

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.

CEO
Mr. J. J. Finkelstein
Employee
2
Address
15245 Shady Grove Road
Rockville, 20850

RegeneRx Biopharmaceuticals, Inc. Executives & BODs

RegeneRx Biopharmaceuticals, Inc. Executives & BODs
# Name Age
1 Mr. J. J. Finkelstein
President, Chief Executive Officer & Director
70
2 Dr. Allan L. Goldstein Ph.D.
Founder, Chairman, Chief Scientific Officer & Chairman of Scientific Advisor Board
70

RegeneRx Biopharmaceuticals, Inc. Competitors